AstraZeneca has stopped selling Andexxa, a factor Xa inhibitor anticoagulant reversal agent the FDA first approved in 2018, because patients may face an increased risk of experiencing a blood clot or stroke. The company emphasized that it remains confident in the agent's abilities.
The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.
Patients first sued the St. Louis Park, Minnesota-based imaging group in two separate lawsuits, both filed in 2023, over its use of tracking pixels to allegedly filter info to Facebook and other third parties.
Founded in 2023, Hunterbrook is an investigative news and investment outlet, which creates reports criticizing publicly traded companies and then benefits from the corresponding drop in share prices
The U.S. Department of Justice has formally accused Done Global of unlawfully distributing ADHD medications without medical need, using a subscription program and targeted advertising to find patients searching for drugs. The company is also accused of filing false medical claims to Medicare, Medicaid and commercial insurance. Done's founder and CEO was convicted last month on related charges and awaits sentencing.
“Physical AI agents being able to actually deliver some of these services—all the way into robotic surgery—this is where we're going to see this next chapter of medicine be written,” said Kimberly Powell, vice president and general manager of healthcare at Nvidia.
The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.
AstraZeneca has stopped selling Andexxa, a factor Xa inhibitor anticoagulant reversal agent the FDA first approved in 2018, because patients may face an increased risk of experiencing a blood clot or stroke. The company emphasized that it remains confident in the agent's abilities.
The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.
